Author Correction: Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells
Yue-qin Wang1,
Ai-jun Shen2,
Jing-ya Sun2,
Xin Wang2,
Hong-chun Liu2,
Min-min Zhang2,
Dan-qi Chen3,
Bing Xiong3,
Jing-kang Shen3,
Mei-yu Geng2,
Min Zheng4,
Jian Ding2
1 Department of New Drug Screening Center, China Pharmaceutical University, Nanjing 210009, China
2 Division of Anti-tumor Pharmacology, Synthetic Organic and Medicinal Chemistry Laboratory, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
3 Synthetic Organic and Medicinal Chemistry Laboratory, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
4 Department of Thoracic Surgery, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China
Correspondence to: Mei-yu Geng: mygeng@simm.ac.cn, Min Zheng: zhengmin8010@126.com, Jian Ding: jding@simm.ac.cn,
DOI: 10.1038/s41401-019-0341-6
Advance online: 21 February 2020
Abstract
It just came to the author’s attention that three errors were introduced into the paper during the stage of figure preparation. Specifically, the Western blotting bands of GAPDH in Fig. 2b as well as Fig. 3b, cv PARP in HCC827/GR6 cells (Fig. 3b) and IHC staining images of EGFR and Hsp70 in group gefitinib 50 mg/kg (Fig. 5d) were found to be misplaced inadvertently. These errors were made completely by accident. Under no circumstance did the authors falsify or “make up” data in order to mislead the reviewers or readers.
Keywords:
N/A
